GlassScriptPhysician profile
Amanda Jones
NPI 1396350559
$1,172.41
in general payments reported to CMS, 2019-2025
16 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $283 · 2023: $187 · 2024: $212 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.04 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $211.04 | 2023-2025 | |
| Astellas Pharma US INC | $182.15 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $167.78 | 2021-2024 | Glassia |
| Evofem Biosciences, INC. | $77.07 | 2022-2025 | Phexxi, Solosec, Phexx |
| Daiichi Sankyo INC. | $60.03 | 2022 | |
| Shield Therapeutics INC | $44.88 | 2024-2025 | |
| Organon LLC | $40.70 | 2023-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $32.35 | 2022-2023 | Aptima |
| Davol INC. | $24.14 | 2024 | Arista Ah Flexitip |
| Millicent US INC | $17.86 | 2025 | Femlyv |
| Abbvie INC. | $17.06 | 2024 | |
| Becton, Dickinson and Company | $16.06 | 2022 | |
| Therapeuticsmd, INC. | $15.76 | 2022 | |
| Sage Therapeutics, LLC | $13.31 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.